PL4063364T3 - Związki pirolotriazyny działające jako inhibitory mnk - Google Patents
Związki pirolotriazyny działające jako inhibitory mnkInfo
- Publication number
- PL4063364T3 PL4063364T3 PL20889927.8T PL20889927T PL4063364T3 PL 4063364 T3 PL4063364 T3 PL 4063364T3 PL 20889927 T PL20889927 T PL 20889927T PL 4063364 T3 PL4063364 T3 PL 4063364T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds acting
- mnk inhibitor
- pyrrolotriazine compounds
- pyrrolotriazine
- mnk
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911129114 | 2019-11-18 | ||
| CN202010329964 | 2020-04-24 | ||
| PCT/CN2020/129603 WO2021098691A1 (zh) | 2019-11-18 | 2020-11-18 | 作为mnk抑制剂的吡咯并三嗪类化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4063364T3 true PL4063364T3 (pl) | 2025-01-20 |
Family
ID=75981354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20889927.8T PL4063364T3 (pl) | 2019-11-18 | 2020-11-18 | Związki pirolotriazyny działające jako inhibitory mnk |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12492215B2 (pl) |
| EP (1) | EP4063364B1 (pl) |
| JP (1) | JP7311207B2 (pl) |
| KR (1) | KR102792835B1 (pl) |
| CN (1) | CN114728966B (pl) |
| AU (1) | AU2020387982B2 (pl) |
| BR (1) | BR112022009563A2 (pl) |
| CA (1) | CA3158749C (pl) |
| DK (1) | DK4063364T3 (pl) |
| ES (1) | ES2993664T3 (pl) |
| FI (1) | FI4063364T3 (pl) |
| HR (1) | HRP20241540T1 (pl) |
| HU (1) | HUE068905T2 (pl) |
| LT (1) | LT4063364T (pl) |
| MX (1) | MX2022005951A (pl) |
| PH (1) | PH12022551226A1 (pl) |
| PL (1) | PL4063364T3 (pl) |
| PT (1) | PT4063364T (pl) |
| SI (1) | SI4063364T1 (pl) |
| WO (1) | WO2021098691A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117355528B (zh) * | 2021-05-08 | 2024-06-21 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物的盐型、其晶型及其制备方法 |
| WO2024017229A1 (zh) * | 2022-07-19 | 2024-01-25 | 成都嘉葆药银医药科技有限公司 | 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024370366A1 (en) * | 2023-11-03 | 2026-06-18 | Jumbo Drug Bank Co., Ltd. | Use of pyrrolotriazine compound in preparation of drug for preventing and/or treating fibrosis or related disease thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US7405213B2 (en) | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| WO2015091156A1 (en) * | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| AU2016252038B2 (en) | 2015-04-20 | 2021-08-12 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| CA3002558A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| SG11201803242TA (en) | 2015-10-29 | 2018-05-30 | Effector Therapeutics Inc | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
| WO2017087808A1 (en) * | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
| WO2017117052A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| CA3050599A1 (en) * | 2017-01-20 | 2018-07-26 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridinpyrimidines |
| DK3582776T3 (da) | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| CA3064000A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| CN117355528B (zh) * | 2021-05-08 | 2024-06-21 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物的盐型、其晶型及其制备方法 |
-
2020
- 2020-11-18 MX MX2022005951A patent/MX2022005951A/es unknown
- 2020-11-18 AU AU2020387982A patent/AU2020387982B2/en active Active
- 2020-11-18 DK DK20889927.8T patent/DK4063364T3/da active
- 2020-11-18 CN CN202080080586.0A patent/CN114728966B/zh active Active
- 2020-11-18 EP EP20889927.8A patent/EP4063364B1/en active Active
- 2020-11-18 LT LTEPPCT/CN2020/129603T patent/LT4063364T/lt unknown
- 2020-11-18 CA CA3158749A patent/CA3158749C/en active Active
- 2020-11-18 BR BR112022009563A patent/BR112022009563A2/pt unknown
- 2020-11-18 WO PCT/CN2020/129603 patent/WO2021098691A1/zh not_active Ceased
- 2020-11-18 HR HRP20241540TT patent/HRP20241540T1/hr unknown
- 2020-11-18 KR KR1020227020316A patent/KR102792835B1/ko active Active
- 2020-11-18 HU HUE20889927A patent/HUE068905T2/hu unknown
- 2020-11-18 PH PH1/2022/551226A patent/PH12022551226A1/en unknown
- 2020-11-18 FI FIEP20889927.8T patent/FI4063364T3/fi active
- 2020-11-18 ES ES20889927T patent/ES2993664T3/es active Active
- 2020-11-18 PT PT208899278T patent/PT4063364T/pt unknown
- 2020-11-18 PL PL20889927.8T patent/PL4063364T3/pl unknown
- 2020-11-18 SI SI202030527T patent/SI4063364T1/sl unknown
- 2020-11-18 JP JP2022528959A patent/JP7311207B2/ja active Active
-
2022
- 2022-05-18 US US17/664,026 patent/US12492215B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220101686A (ko) | 2022-07-19 |
| SI4063364T1 (sl) | 2025-02-28 |
| KR102792835B1 (ko) | 2025-04-07 |
| FI4063364T3 (fi) | 2024-11-19 |
| US20220281895A1 (en) | 2022-09-08 |
| LT4063364T (lt) | 2024-11-11 |
| US12492215B2 (en) | 2025-12-09 |
| JP2023502237A (ja) | 2023-01-23 |
| PH12022551226A1 (en) | 2023-06-14 |
| AU2020387982B2 (en) | 2023-08-03 |
| ES2993664T3 (en) | 2025-01-03 |
| HRP20241540T1 (hr) | 2025-01-03 |
| BR112022009563A2 (pt) | 2022-08-02 |
| CN114728966B (zh) | 2023-08-18 |
| CN114728966A (zh) | 2022-07-08 |
| WO2021098691A1 (zh) | 2021-05-27 |
| CA3158749A1 (en) | 2021-05-27 |
| EP4063364A1 (en) | 2022-09-28 |
| HUE068905T2 (hu) | 2025-02-28 |
| EP4063364A4 (en) | 2023-12-13 |
| AU2020387982A1 (en) | 2022-06-30 |
| MX2022005951A (es) | 2022-07-27 |
| PT4063364T (pt) | 2024-10-30 |
| JP7311207B2 (ja) | 2023-07-19 |
| DK4063364T3 (da) | 2024-11-25 |
| CA3158749C (en) | 2024-11-19 |
| EP4063364B1 (en) | 2024-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE068905T2 (hu) | MNK-gátlóként ható pirrolotriazin vegyületek | |
| SG11202103839UA (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| IL289463A (en) | Agonist-gipr compounds | |
| GB201914860D0 (en) | Inhibitor compounds | |
| IL290087A (en) | inhibitory substances | |
| IL292093A (en) | Thianopyrimidones as trpa1 inhibitors | |
| GB202008201D0 (en) | Inhibitor compounds | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL292095A (en) | Thianopyrimidones as trpa1 inhibitors | |
| GB202004960D0 (en) | Inhibitor compounds | |
| GB201905328D0 (en) | Inhibitor compounds | |
| IL269144A (en) | Pyrrolotriazine derivatives as kinase inhibitors | |
| GB202110373D0 (en) | Inhibitor compounds | |
| IL288472A (en) | Tetracyclic compounds as cdc7 inhibitors | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201908171D0 (en) | Compounds | |
| GB202117224D0 (en) | Inhibitor compounds | |
| GB202012969D0 (en) | Inhibitor compounds | |
| GB201905318D0 (en) | Inhibitor compounds | |
| AU2019902614A0 (en) | Inhibitor compounds | |
| GB202112240D0 (en) | Inhibitor compounds | |
| GB202107325D0 (en) | Inhibitor compounds | |
| GB202104781D0 (en) | Inhibitor compounds | |
| GB202016964D0 (en) | Inhibitor compounds | |
| GB202008205D0 (en) | Inhibitor compounds |